SC
Sequoia China
Beijing, ChinaFounded 2005
Sequoia China, now operating as HongShan, focuses its investments on high-growth potential companies primarily within the technology (including AI, e-commerce, and fintech), healthcare, and consumer sectors. Their strategy involves a highly selective approach, meticulously analyzing market trends, management teams, and business model scalability, while investing across various stages from early-stage to growth and pre-IPO.
Portfolio
10
Fund Size
$55B
Top Stage
Series B
Last 12 Mo
0
Stage Distribution
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Airwallex | Series E | $400M | Oct 2022 |
| Dianxiaomi | Series D | $110M | Aug 2022 |
| SyMap Medical Ltd. | Growth | $100M | Dec 2021 |
| Q-CTRL | Series B | $25M | Nov 2021 |
| SmartMore | Series C | $200M | Jun 2021 |
| Phanes Therapeutics | Series B | $40M | May 2021 |
| XtalPi | Series A | $15M | Jan 2018 |
| OPay | Series B | $120M | — |
| XtalPi Inc. | Series D | — | — |
| Xtalpi | Series D | — | — |
Top Co-Investors
Tencent Investment4 shared
Zhenfund3 shared
GV (Google Ventures)3 shared
IDG Capital2 shared
SoftBank Vision Fund2 shared
Susquehanna2 shared
Meituan-Dianping1 shared
Gaorong Capital1 shared
Source Code Capital1 shared
SoftBank Ventures Asia1 shared
GSR Ventures1 shared
DST Global1 shared
5Y Capital1 shared
Tiger Global Management1 shared
GGV Capital1 shared
Airbus Ventures1 shared
Main Sequence1 shared
Horizon Ventures1 shared
Square Peg Capital1 shared
Sierra Ventures1 shared
Last updated: 27 February 2026